Pakistan Journal of Pharmaceutical Sciences

Abstract: Bronchopneumonia is an extremely common respiratory disease in children, which may cause bronchiectasis, respiratory failure, and other complications. In this study, we observed the effect of acetylcysteine combined with diphylline in the treatment of bronchopneumonia. This includes the session time of the child's cough and wheezing symptoms, lung function, and the inflammatory response before and after treatment. In addition, we also counted the adverse reactions during the treatment of the children. The results of the study showed that children in the research group treated with acetylcysteine combined with diphylline had a shorter time to symptomatic relief compared to the control group using bronchopneumonia (P<0.05). Also, the lung function after treatment was better in the research group than in the control group, and the levels of inflammatory factors were lower in the research group than in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). These results suggest that acetylcysteine combined with diphylline has excellent potential for the treatment of bronchopneumonia.